In a £4.46bn all-cash deal, Dechra Pharmaceuticals has agreed to be acquired by Swedish private equity firm EQT and Luxinva, a subsidiary of Abu Dhabi Investment Authority (ADIA).
In a £4.46bn all-cash deal, Dechra Pharmaceuticals has agreed to be acquired by Swedish private equity firm EQT and Luxinva, a subsidiary of Abu Dhabi Investment Authority (ADIA).
All the week’s industry events straight to your inbox.
By signing up you agree to our terms of use and privacy policy.
7 Bell Yard, London, England, WC2A 2JR
You will soon receive a Reset Password link
By signing up you agree to terms of use and privacy policy.
Continue with Facebook Continue with Google